Selecting Between Doublet and Triplet Regimens for Patients With Transplant-Ineligible NDMM
April Logue, APRN-CNP, shares her perspective on selecting between doublet and triplet regimens for patients with transplant-ineligible newly-diagnosed multiple myeloma.
Video Player is loading.
EP: 1.Personalized Therapy Options Are on the Horizon in Multiple Myeloma
EP: 2.Treatment Approaches for Patients With Newly-Diagnosed Multiple Myeloma (NDMM)
EP: 3.Transplant Eligibility in Patients With NDMM
EP: 4.Treatment Considerations for Patients with High-Risk NDMM
EP: 5.First-Line Treatment Options for Patients With Transplant-Ineligible NDMM
EP: 6.Data Updates on the Treatment of Transplant-Ineligible NDMM From the MAIA Trial
Now Viewing
EP: 7.Selecting Between Doublet and Triplet Regimens for Patients With Transplant-Ineligible NDMM
EP: 8.Available Treatment Options for Patients with Relapsed Multiple Myeloma
EP: 9.Updates on Bispecific T-Cell Engager (BiTE) Antibodies in Relapsed Multiple Myeloma
EP: 10.Other Bispecific Antibodies Under Investigation for Treatment of Relapsed Multiple Myeloma
EP: 11.CAR T-Cell Therapy vs Bispecific Antibodies for Patients With Refractory Multiple Myeloma
EP: 12.Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple Myeloma
Recent Videos
Managing Epithelioid Sarcoma: Follow-Up Strategies and Treatment Decisions for Stable Disease vs Progression
Navigating Frontline Therapy in Epithelioid Sarcoma: Key Clinical Considerations and Shared Decision-Making
Optimizing Multidisciplinary Coordination for Successful Tarlatamab Implementation
Institutional Implementation: Setting Up Tarlatamab Administration
Choosing Between Tazemetostat and Zanubrutinib+Obinutuzumab: Key Factors & Patient Conversations
Expert Perspectives: Tazemetostat in R/R FL
Management Strategies for Localized Epithelioid Sarcoma: The Role of Neoadjuvant and Adjuvant Therapies
Key Takeaways and Future Perspectives: PSMA PET Imaging in Prostate Cancer
Evaluating the Role of Cu-PSMA PET Imaging in Prostate Cancer
A 62-Year-Old Woman With Epithelioid Sarcoma Treated With Tazemetostat
Related Content
!["[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fb319d51b3dcc8ae143eae44a72a0aff757b330db-800x533.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation,\" according to the study authors.")
![“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F4de1e119837b011168a7884a19a600b14bb6a258-3600x2400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.")
